Oncology

Metastatic Breast Cancer

Conference Reporter® in HR+/HER2- Metastatic Breast Cancer to Cover Key Topics Being Presented at ASCO 2026

conference reporter by Adam M. Brufsky, MD, PhD; Komal Jhaveri, MD, FACP, FASCO

Overview

Conference Reporter delivers health care providers with insights from key thought leaders on exciting news presented at major medical conferences, in a concise and timely format. Conference Reporter will feature community-selected experts and topics in HR+/HER2- Metastatic Breast Cancer presented at the 2026 ASCO Annual Meeting.

VIEW THE TOPICS:

After CDK4/6 Inhibition: Which Biomarkers Should Guide the Next Treatment Choice in HR+/HER2- Metastatic Breast Cancer?
ctDNA-Guided Therapy Switching in Metastatic HR+/HER2- Breast Cancer
Emerging Treatment Strategies in Metastatic HR+/HER2- Breast Cancer: ASCO Highlights
PI3K Pathway Targeting and Implications for Treatment of Metastatic HR+/HER2- Breast Cancer

This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.

2026 ASCO Annual Meeting

May 29 – June 2, 2026

McCormick Place

Chicago, IL

Registration Link

Profile

Adam M. Brufsky, MD, PhD

Professor of Medicine
Codirector, Cancer Therapeutics Program
UPMC Hillman Cancer Center
University of Pittsburgh School of Medicine
Pittsburgh, PA

Profile

Komal Jhaveri, MD, FACP, FASCO

Associate Attending Physician, Breast Medicine and Early Drug Development Services
Section Head, Endocrine Therapy Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
New York, NY